NEW YORK (
CHANGE IN RATINGS
was upgraded at Topeka Capital to buy. $18 price target. New fashion is impressive, Topeka said.
was downgraded at Wells Fargo to underperform from market perform. Stock is trading at a 20% premium to its historical valuation, Wells Fargo said.
(FLIR - Get Report)
was downgraded at Drexel Hamilton to hold from buy. Stock is trading at historically high and unwarranted multiples, Drexel Hamilton said. Downgraded on valuation.
Magellan Health Services
(MGLN - Get Report)
was downgraded at Citigroup to sell from neutral. The loss of four contracts account is not appropriately captured by consensus, Citi said.
was upgraded to buy at TheStreet Ratings.
(NDAQ - Get Report)
was downgraded at Goldman Sachs to sell from neutral. Price target is $28. Shift to lower margin revenue sources will hurt future earnings, Goldman said.
was upgraded to hold at TheStreet Ratings.
(PHM - Get Report)
was upgraded at UBS to buy from neutral and given a $22 price target. The stock is undervalued given leverage from Del Webb, margin expansion and focus on maximizing returns, UBS said.
(PHM - Get Report)
was upgraded at Williams Financial Group to buy from hold. Price target is $21. Community count expansion is expected to drive new order growth.
was upgraded to buy from hold at Deutsche Bank. $150 price target. Elan acquisition enhances the company's outlook, Deutsche said.
was upgraded to buy at Bank of America/Merrill Lynch. $22 price target. Trends are improving, and the stock is trading at an attractive valuation, BofA/Merrill said.
(RYL - Get Report)
was upgraded at UBS to buy from neutral and given a $48 price target. Higher ROE and improving profitability justify higher multiple, UBS said.
was downgraded at Citigroup to neutral from buy and given a $37 price target. Indigo Partners plans to sell all of its remaining shares, Citi said.
was initiated at Key Bank with a hold rating. The transition to a lifestyle brand and the addition of women's products are cited as the key growth factors, Key Bank said.
Stock Comments / EPS Changes
numbers were cut at UBS. Earnings estimates were reduced on updated guidance, said UBS. Price target is $105.